Blueprint Medicines Corp Stock Performance
| BPMC Stock | USD 129.46 0.18 0.14% |
On a scale of 0 to 100, Blueprint Medicines holds a performance score of 15. The firm shows a Beta (market volatility) of 0.17, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Blueprint Medicines' returns are expected to increase less than the market. However, during the bear market, the loss of holding Blueprint Medicines is expected to be smaller as well. Please check Blueprint Medicines' expected short fall, day median price, and the relationship between the potential upside and accumulation distribution , to make a quick decision on whether Blueprint Medicines' price patterns will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Blueprint Medicines Corp are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating primary indicators, Blueprint Medicines exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.14 | Five Day Return 0.12 | Year To Date Return 48.46 | Ten Year Return 308.26 | All Time Return 586.06 |
1 | Disposition of 529 shares by Christina Rossi of Blueprint Medicines at 108.99 subject to Rule 16b-3 | 05/09/2025 |
2 | BPMC Needham Downgrades Blueprint Medicines to Hold, Price Target Unchanged BPMC Stock News | 06/02/2025 |
3 | BPMC Stock Upgraded Citigroup Raises Price Target Significantly BPMC Stock News | 06/04/2025 |
4 | Blueprint Medicines Corp Showcases Long-Term Efficacy of | 06/12/2025 |
5 | Best Growth Stocks To Watch Now June 17th | 06/18/2025 |
6 | Blueprint Medicines Presents Strong Long-Term Data for AYVAKIT in Systemic Mastocytosis | 06/24/2025 |
7 | Disposition of 1051 shares by Carter Percy H. of Blueprint Medicines at 128.25 subject to Rule 16b-3 | 07/03/2025 |
8 | China Universal Asset Management Co. Ltd. Sells 652 Shares of Blueprint Medicines Corporation | 07/09/2025 |
9 | Top Growth Stocks To Follow Today July 8th | 07/11/2025 |
10 | HAREHOLDER ALERT The MA Class Action Firm Announces An Investigation of Blueprint Medicines Corporation | 07/14/2025 |
11 | Top Mid Cap Stocks To Follow Now July 14th | 07/15/2025 |
12 | Press Release Sanofi announces extension of Blueprint tender offer | 07/17/2025 |
| Begin Period Cash Flow | 81.5 M | |
| Total Cashflows From Investing Activities | -47.5 M |
Blueprint | Build AI portfolio with Blueprint Stock |
Blueprint Medicines Relative Risk vs. Return Landscape
If you would invest 8,418 in Blueprint Medicines Corp on April 21, 2025 and sell it today you would earn a total of 4,528 from holding Blueprint Medicines Corp or generate 53.79% return on investment over 90 days. Blueprint Medicines Corp is currently generating 0.765% in daily expected returns and assumes 3.9505% risk (volatility on return distribution) over the 90 days horizon. In different words, 35% of stocks are less volatile than Blueprint, and 85% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Blueprint Medicines Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Blueprint Medicines' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Blueprint Medicines Corp, and traders can use it to determine the average amount a Blueprint Medicines' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1936
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BPMC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.95 actual daily | 35 65% of assets are more volatile |
Expected Return
| 0.77 actual daily | 15 85% of assets have higher returns |
Risk-Adjusted Return
| 0.19 actual daily | 15 85% of assets perform better |
Based on monthly moving average Blueprint Medicines is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Blueprint Medicines by adding it to a well-diversified portfolio.
Blueprint Medicines Fundamentals Growth
Blueprint Stock prices reflect investors' perceptions of the future prospects and financial health of Blueprint Medicines, and Blueprint Medicines fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Blueprint Stock performance.
| Return On Equity | -0.48 | ||||
| Return On Asset | -0.0975 | ||||
| Profit Margin | (0.28) % | ||||
| Operating Margin | (0.28) % | ||||
| Current Valuation | 8.24 B | ||||
| Shares Outstanding | 64.58 M | ||||
| Price To Earning | 7.93 X | ||||
| Price To Book | 24.42 X | ||||
| Price To Sales | 14.89 X | ||||
| Revenue | 508.82 M | ||||
| Gross Profit | 542.35 M | ||||
| EBITDA | 19.23 M | ||||
| Net Income | (67.09 M) | ||||
| Cash And Equivalents | 853.11 M | ||||
| Cash Per Share | 14.28 X | ||||
| Total Debt | 126.05 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 6.00 X | ||||
| Book Value Per Share | 5.30 X | ||||
| Cash Flow From Operations | (192.59 M) | ||||
| Earnings Per Share | (2.51) X | ||||
| Market Capitalization | 8.37 B | ||||
| Total Asset | 1.18 B | ||||
| Retained Earnings | (2.41 B) | ||||
| Working Capital | 481.88 M | ||||
| Current Asset | 170.42 M | ||||
| Current Liabilities | 18.64 M | ||||
About Blueprint Medicines Performance
By analyzing Blueprint Medicines' fundamental ratios, stakeholders can gain valuable insights into Blueprint Medicines' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Blueprint Medicines has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Blueprint Medicines has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 246.39 | 234.07 | |
| Return On Tangible Assets | (0.06) | (0.06) | |
| Return On Capital Employed | (0.23) | (0.24) | |
| Return On Assets | (0.06) | (0.06) | |
| Return On Equity | (0.22) | (0.21) |
Things to note about Blueprint Medicines Corp performance evaluation
Checking the ongoing alerts about Blueprint Medicines for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Blueprint Medicines Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Blueprint Medicines appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 508.82 M. Net Loss for the year was (67.09 M) with profit before overhead, payroll, taxes, and interest of 542.35 M. | |
| Blueprint Medicines Corp currently holds about 853.11 M in cash with (192.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.28. | |
| Blueprint Medicines has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Press Release Sanofi announces extension of Blueprint tender offer |
- Analyzing Blueprint Medicines' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Blueprint Medicines' stock is overvalued or undervalued compared to its peers.
- Examining Blueprint Medicines' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Blueprint Medicines' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Blueprint Medicines' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Blueprint Medicines' stock. These opinions can provide insight into Blueprint Medicines' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Blueprint Stock analysis
When running Blueprint Medicines' price analysis, check to measure Blueprint Medicines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Blueprint Medicines is operating at the current time. Most of Blueprint Medicines' value examination focuses on studying past and present price action to predict the probability of Blueprint Medicines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Blueprint Medicines' price. Additionally, you may evaluate how the addition of Blueprint Medicines to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |